Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren’s disease.
Based on their laboratory data that tumour necrosis factor (TNF) drives the development of myofibroblasts, the cell type that causes Dupuytren’s disease, the research team explored the effect of an anti-TNF drug injected directly into the Dupuytren’s nodule tissue. The results so far are very promising.
“Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren’s disease,” said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.
“This brings new hope to people who suffer from this disabling condition, who currently have to wait for their situation to be deteriorate, watching their hand lose function until it is bad enough for surgery. And then there’s the lengthy recovery ahead, a less than ideal situation to find yourself in.”
This randomised trial (phase 2a) recruited 28 patients with Dupuytren’s disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand. Two weeks prior to surgery they received a single injection of varying doses of the anti-TNF drug, or placebo. The tissue removed during surgery, which is usually discarded, was then analysed in the laboratory. The team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells. They also found the drug to be safe and well tolerated.
The findings are published on line in the journal EBioMedicine, published by The Lancet.
Dupuytren’s disease is a common condition of the hand that affects 4% of the UK population and causes the fingers to curl irreversibly into the palm. There is currently no NICE approved treatment for early disease and typically people are told to return to their GP once their fingers become so bent that their hand function is impaired.
The anti-TNF drug adalimumab (Humira) is currently licensed in the EU for the treatment of a number of conditions including rheumatoid arthritis, Crohn’s disease and ulcerative colitis and overall has an excellent safety profile.
“We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren’s disease,” said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute. In conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.
“The Kennedy Institute has a long history of successfully translating laboratory findings to the clinic'” said Professor Fiona Powrie, Director of the Institute. “This type of work requires close collaboration between laboratory scientists, clinical trialists and clinician scientists over many years”.
The researchers are continuing to investigate the use of this drug to treat Dupuytren’s disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.
The Latest on: Dupuytren’s disease
via Google News
The Latest on: Dupuytren’s disease
- Study: Peyronie's disease which causes curvature in penis, linked to health issues on September 6, 2018 at 4:12 am
In order to do this, scientists sequenced full sets of genes from a father and son. One had Peyronie’s disease while the other had an associated problem called Dupuytren’s contracture. Dupuytren’s con... […]
- Here's Why Endo International plc Jumped 37.9% Higher in August on September 5, 2018 at 7:00 am
Yikes. Fortunately, most of the rest of Endo's products are doing well. Sales of Xiaflex, which treats a pair of rare diseases called Dupuytren's contracture and Peyronie's disease, jumped 27% year ov... […]
- 180 Therapeutics Announces Positive Results from a Phase 2a Clinical Trial of Anti-TNF Therapy in Dupuytren’s Disease on July 31, 2018 at 5:23 am
CAMBRIDGE, Mass.--(Business Wire)--180 Therapeutics LP, a clinical stage biopharmaceutical company focused on the discovery and development of novel biologic therapies for the treatment of fibrosis, a ... […]
- Patients with hand disabling Dupuytren's can now hope for a cure on July 8, 2018 at 1:03 am
Patients with incurable hand disabling condition, called Dupuytren's disease, have a ray of hope. Dupuytren's disease is a common condition that causes the fingers to curl irreversibly into the palm. ... […]
- New hope for patients with incurable and disabling hand condition, Dupuytren's disease on July 6, 2018 at 8:09 am
Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that i... […]
- Dupuytren’s: Man with ‘Viking’s Disease’ supports campaign over hand condition on June 20, 2018 at 11:00 pm
A BRADFORD man who lives with a debilitating hand condition has spoken out about the lack of awareness surrounding the disease. Ian Ireland, 65, from East Morton has Dupuytren’s which is also known as ... […]
- NICE recommends Xiapex for NHS in England to treat Dupuytren’s contracture on July 2, 2017 at 9:45 pm
Swedish Orphan Biovitrum AB (Sobi) announced that for the first time people in England with the disabling hand condition Dupuytren’s disease will have access to Xiapex (collagenase clostridium histoly... […]
- UPHS - Marquette Hand Surgeon receives international recognition for work on 'Viking disease,' Dupuytren’s contracture on January 18, 2017 at 7:42 am
MARQUETTE, Mich. (WLUC) - A local surgeon has received international recognition for his research on the treatment of a disease that has a big impact in the Upper Peninsula. Dr. Clayton Peimer is a ce... […]
- Endo pharmaceuticals presents new Phase 2 data for XIAFLEX for Dupuytren's Disease Nodules on September 30, 2016 at 6:53 am
Endo Pharmaceuticals (ENDP) announces that new data will be presented evaluating the safety and efficacy of XIAFLEX (collagenase clostridium histolyticum) (CCH) injection under investigation for the t... […]
via Bing News